2021 Pipeline Insight Report on Myocardial Infarction - Featuring AstraZeneca, Mesoblast and Boehringer Ingelheim Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 30, 2021--
The “Myocardial Infarction - Pipeline Insight, 2021” clinical trials have been added to ResearchAndMarkets.com’s offering.
This “Myocardial infarction - Pipeline Insight, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Myocardial infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial infarction R&D. The therapies under development are focused on novel approaches to treat/improve Myocardial infarction.
Myocardial infarction Emerging Drugs Chapters
This segment of the Myocardial infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Myocardial infarction Emerging Drugs
Dapagliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor with antihyperglycemic activity. Dapagliflozin selectively and potently inhibits SGLT2 compared to SGLT1, which is the cotransporter of glucose in the gut. The drug is in phase 3 of clinical trials for the treatment of Myocardial infarction.
AAV-AQP1 is an Adeno-associated virus vector containing gene therapy that contains the human aquaporin-1 gene (AAV2hAQP1) for the treatment of Myocardial infarction. It works on Aquaporin 1 replacement mechanism. It is currently under Phase I/II stage of development. Remestemcel-L is an investigational therapy comprising culture-expanded mesenchymal stromal cells derived from the bone marrow of an unrelated donor. Remestemcel-L is thought to have immunomodulatory properties to counteract the cytokine storms that are implicated in various inflammatory conditions by downregulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues. The drug is in phase 2 of clinical trials for the treatment of Myocardial infarction.
Myocardial infarction: Therapeutic Assessment
This segment of the report provides insights about the different Myocardial infarction drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Myocardial infarction
There are approx. 50+ key companies which are developing the therapies for Myocardial infarction. The companies which have their Myocardial infarction drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.
This report covers around 50+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Myocardial infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Myocardial infarction: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myocardial infarction therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocardial infarction drugs.
Myocardial infarction Report Insights
- Myocardial infarction Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Myocardial infarction Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Myocardial infarction drugs?
- How many Myocardial infarction drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocardial infarction?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocardial infarction therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Myocardial infarction and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- PT. Prodia Stem Cell Indonesia
- Honya Medical Inc
- Ever Supreme Bio Technology
- Athera Biotechnologies
- Polyphor Ltd.
- Idorsia Pharmaceuticals
- Faraday Pharmaceuticals
- CSL Behring
- Recardio, Inc.
- Quantum Genomics
- CeleCor Therapeutics
- Shanghai Life Science & Technology
- Dexa Medica Group
- LG Life Sciences
- Synokem Pharmaceuticals
- Windtree Therapeutics
- Quark Pharmaceuticals
- Actelion Pharmaceuticals
- Bharat Biotech
- Cynata Therapeutics
- HUYA Bioscience
- Lee’s Pharmaceutical
- NuvOx Pharma
- OMEICOS Therapeutics
- Quark Pharmaceuticals
- Rubicon Biotechnology
- Silver Creek Pharmaceuticals
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/i2f9gu
View source version on businesswire.com:https://www.businesswire.com/news/home/20210830005246/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 08/30/2021 05:18 AM/DISC: 08/30/2021 05:18 AM